Archive for February, 2009

Five issues that will survive the semiconductor industry’s nuclear winter - Part-I.

Submitted by Bapcha’s Stocks

Posted on February 27th, 2009 in ACTL., ALTR, AMAT, Actel, Altera, BRCM, Broadcom, INTC, Intel, KYO, Kyocera, LLTC, LRCX, LSCC, Lam Research, Lattice, Linear Tech, MRVL, MU, MXIM, Marvell, Maxim, Micron, NVDA, NVLS, Novellus, SNDK, SSTI, SanDisk, TXN., Texas Instruments, Uncategorized, XLNX, Xilinx, nVidia Actel, ACTL., Altera, ALTR, AMAT, BRCM, Broadcom, INTC, [...]

Previously…

Submitted by Bapcha’s Stocks
AXP, American Express, Banking Collapse, Banking Collapse of 1933, Bernard Madoff, Bernie Madoff, FDIC, G-S, GLB, GLB Act, GS, Glass-Steagall, Goldman-Sachs, Gramm-Leach-Bliley, MS, Madoff, Morgan-Stanley, Reinstate Glass-Steagall, TARP, Uncategorized American Express, AXP, Banking Collapse, Banking Collapse of 1933, Bernard Madoff, Bernie Madoff, FDIC, G-S, Glass-Steagall, GLB, GLB Act, Goldman-Sachs, Gramm-Leach-Bliley, GS, Madoff, [...]

Drug Makers Fight Stimulus Provision

Submitted by THE HEALTH ECONOMICS BLOG
By ALICIA MUNDY
WASHINGTON — The drug and medical-device industries are mobilizing to gut a provision in the stimulus bill that would spend $1.1 billion on research comparing medical treatments, portraying it as the first step to government rationing.
The fight over the provision is highlighting the tensions behind President Barack Obama’s [...]

Health Economics Position - Grapevinerecruiters

Submitted by THE HEALTH ECONOMICS BLOG
Folks,
this just came in, please contact Darren (see below)
best
Ulf
Associate Director of Health Economics and Outcomes
REPORTS TO: Strategic Affairs
LOCATION: Markham
OVERALL PURPOSE/MAJOR FUNCTION
• Develop timely, appropriate health economic data to support reimbursement initiatives for all products
• Manage economic and outcomes research projects in support of international and local pricing and reimbursement programs
• [...]

NICE splits renal cancer drugs assessment - “yes” for Pfizer’s Sutent, “no” for Roche, Bayer, Wyeth

Submitted by THE HEALTH ECONOMICS BLOG
by Nick Smith
LONDON, Feb 4 (APM) - NICE on Wednesday split its controversial review of renal cancer drugs into two, saying ‘yes’ to Pfizer’s Sutent (sunitinib) but rejecting three others - Wyeth’s Torisel (temsirolimus), Bayer’s Nexavar (sorafenib) and Roche’s Avastin (bevacizumab).
In effect NICE has all but guaranteed that one product [...]

NICE splits renal cancer drugs assessment - “yes” for Pfizer’s Sutent, “no” for Roche, Bayer, Wyeth

Submitted by THE HEALTH ECONOMICS BLOG
by Nick Smith
LONDON, Feb 4 (APM) - NICE on Wednesday split its controversial review of renal cancer drugs into two, saying ‘yes’ to Pfizer’s Sutent (sunitinib) but rejecting three others - Wyeth’s Torisel (temsirolimus), Bayer’s Nexavar (sorafenib) and Roche’s Avastin (bevacizumab).
In effect NICE has all but guaranteed that one product [...]